ClinicalTrials.gg
CompletedNCT00819520Updated Aug 22, 2011

Ivermectin in the Treatment of Head Lice

A Phase 3 interventional study of ivermectin and malathion in Lice Infestations, sponsored by Johnson & Johnson Consumer and Personal Products Worldwide. Completed at 4 sites in 4 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2011-08-22.

Sponsored by Johnson & Johnson Consumer and Personal Products Worldwide (formerly part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
812
Allocation
Randomized
Ages
2 Years and older
Sex
All
01

Study summary

The purpose of this study is to compare 2 single doses of ivermectin as tablets with 2 single applications of malathion 0.5% lotion (Days 1 and 8) in clearing head lice, in patients who have recently used standard head lice treatments without success.

Read the detailed description

Head lice infestation occurs frequently, primarily in children 3 to 11 years of age. In recent years an increasing prevalence of lice infestation in schools, day care centres, and summer day camps is believed to be partly due to increasing lice resistance to currently available standard treatments for pediculosis (infestation with lice). There is a need for new effective backup treatments for this common condition of head lice infestation. This is a double-blind, randomized, parallel-group, study in several clinical centres comparing ivermectin as tablets to malathion 0.5% lotion in the treatment of head lice. All enrolled patients participate in the primary phase of the study up to the Day 15 evaluation. Patients who are still infested with lice at Day 15 (treatment failures) will enter an extension phase and be treated in a double-blind, fashion with the opposite treatment (ie ivermectin or malathion). The study hypothesis is that ivermectin will be more effective than malathion in clearing head lice infestation , as measured by the proportion of patients who are lice-free at Study Day 15.

02

Conditions studied

  • Lice Infestations

Browse trials for

Keywords

  • pediculosis capitis
  • pediculus
03

In context

Lice Infestations

43 studies on the registry are indexed under Lice Infestations; 4 are open to participants now.

This study's enrollment of 812 is above the median of 105 across 42 interventional studies indexed under Lice Infestations.

Browse Lice Infestations studies →

Lead sponsor

Johnson & Johnson Consumer and Personal Products Worldwide is the lead sponsor of 60 studies on the registry; none are open to participants now.

First submitted before Johnson & Johnson Consumer and Personal Products Worldwide left Johnson & Johnson.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Head lice infestation confirmed by detection combing by study staff
  • previous (within 6 weeks) use of a topical insecticide product
  • minimum 15kg weight
  • providing

Exclusion criteria

Exclusion Criteria:

  • pregnant or nursing patients
  • households with 7 or more infested patients
  • households where there are other known infested household members not participating
  • head lice treatment within 2 weeks of entry
  • active scalp infection
  • any difficulty with combing assessment
  • patient from region endemic for certain parasitic worm diseases
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
812 participants (actual)

Study arms

  • Experimental
    Ivermectin

    ivermectin Stromectol®)

    Drug: ivermectin

  • Active comparator
    Malathion

    malathion(Prioderm®)

    Drug: malathion

Interventions

  • Two single doses of oral ivermectin 400 mcg/kg (Days 1 and 8) plus 2 single applications of placebo lotion

    Also known as: Stromectol®

  • Two single applications of malathion 0.5% lotion (Days 1 and 8) plus 2 single doses of placebo tablets

    Also known as: Prioderm®

06

What researchers measure

Primary outcomes

  1. Absence or presence of live head lice

    Time frame: Study Day 15

Secondary outcomes

  1. Absence or presence of live head lice at alternative Study Days.

    Time frame: Study Days 2, 8, 22, 29

  2. Safety Assessments will consist of monitoring and recording all non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs), their frequency, severity, seriousness, and relationship to the investigational product.

    Time frame: throughout duration of the study (+ 30 days for spontaneously reported SAEs)

07

Study locations

4 sites
  • Hopital Avicenne
    Bobigny, Paris 93009, France
  • Shandon Clinic
    Cork, Co. Cork, Ireland
  • Chaim Sheba Medical Centre
    Tel Hashomer, 52621, Israel
  • Synexus Clinical Research Centre
    Reading, Berks RG2 7AG, United Kingdom
08

References and documents

Publications

  • Chosidow O, Giraudeau B, Cottrell J, Izri A, Hofmann R, Mann SG, Burgess I. Oral ivermectin versus malathion lotion for difficult-to-treat head lice. N Engl J Med. 2010 Mar 11;362(10):896-905. doi: 10.1056/NEJMoa0905471. Erratum In: N Engl J Med. 2010 Apr 29;362(17):1647. PubMed 20220184 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2004, a primary completion of Sep 2004 and a completion of Oct 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2009
First posted
Jan 9, 2009
Start
Feb 2004
Primary completionActual
Sep 2004
CompletionActual
Oct 2004
Last update
Aug 22, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00819520
Responsible party
Sponsor
First posted
Jan 9, 2009
Start date
Feb 2004
Primary completion
Sep 2004
Completion
Oct 2004
Last update
Aug 22, 2011

Study contacts

Jerry Cottrell
study director · J&J Consumer and Personal Products Worldwide

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivermectin

Start the discussion